Plain-English translation of NCT07488065 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing SKB575, a new injectable medication designed to treat moderate to severe atopic dermatitis (a chronic skin condition that causes intense itching and inflammation). The study is being conducted in two parts: first testing the medication's safety in healthy volunteers, and then testing whether it actually helps people with atopic dermatitis. Researchers will carefully monitor how the medication works in your body and watch for any side effects.
Atopic dermatitis can be extremely uncomfortable and difficult to manage with current treatments alone. This trial exists to see if this new medication can help reduce inflammation and improve symptoms for people living with moderate to severe forms of this condition.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive injections of either the new medication or a placebo (inactive treatment) at scheduled visits. The study involves blood tests, skin assessments, and follow-up visits to monitor your health and how your skin responds to treatment. Healthy volunteers will participate in the first part, while people with moderate to severe atopic dermatitis will participate in the second part, with visits occurring over several weeks to months depending on the study design.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China